生命科学资讯

CMS proposes two long-awaited Medicare drug pricing demos

China's new commercial insurance model could broaden access to Alzheimer's drugs

Bristol Myers brings IRA drug pricing fight to Supreme Court

US charges six people with insider trading in case including Olema Oncology

Windward gets bispecific from Qyuns in its second China deal of the year

Shionogi will pay $2.5B to acquire one of the only approved ALS drugs

Ipsen gains access to ADC from Shanghai biotech Simcere Zaiming

Boehringer taps Rectify to create pills for chronic kidney disease

AstraZeneca bets up to $2B on Jacobio’s pan-KRAS inhibitor for cancer

Aktis Oncology files for IPO to fund Lilly-partnered radiopharma pipeline

Nine more MFN deals; Western drugmakers turn to China; Chai Discovery's raise; and more

FDA approves Cytokinetics’ heart drug, giving it an edge over BMS rival

White House unveils nine new ‘most favored nation’ deals

Galapagos' last asset posts mixed results as future remains in flux

BioMarin to pay $4.8B for Amicus and its rare disease drugs

Senators point fingers over who blocked the rare disease voucher reauthorization

Altimmune advances in MASH; New China obesity biotech; Ipsen Phase 2 fail

Joe Jimenez's Aditum goes to Fosun for major biobuck-loaded collaboration

Catalent handed two Form 483s, including for Sarepta gene therapy site

Endpoints at JPM 2026: What we'll be talking about